Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $95.11
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.00M
Market Cap
$9.72B
Enterprise Value$3.88K
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)201.2
Beta0.51
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume1,005,173
30 Day Avg. Volume1,004,040
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$97.50Price Target Upside111.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.59
Revenue Forecast (FY)$976.58M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable equity base give Corcept durable financial flexibility to fund multi-year clinical programs and commercial launches without near-term refinancing risk. This cushion supports pipeline investment and buffers execution setbacks over the next several quarters.
Lifyorli Approval With Survival BenefitA pivotal approval showing a large survival benefit creates a durable clinical and commercial advantage in platinum-resistant ovarian cancer. Strong efficacy and guideline inclusion broaden the addressable market and support multi-year oncology revenues beyond the legacy endocrine franchise.
Healthy Cash RunwayA strong cash position provides runway to absorb launch and development spending, scale specialty pharmacy operations, and fund pivotal trials. This reduces near-term dilution risk and enables sustained investment in commercialization and R&D over the coming 2–4 years.
Bears Say
Eroding ProfitabilityWhile gross margins remain very high, operating expenses tied to launches and R&D have compressed net margins materially. Continued margin erosion could weaken returns on equity and gradually erode the balance sheet cushion, limiting optionality for future investments.
Operational Scaling And Prior‑auth BacklogTransitioning patients and a single‑pharmacy capacity constraint caused payer authorization delays that reduce revenue recognition and patient access. If operational scale-up lags, durable adoption and steady revenue realization from new launches may be impaired.
Prolonged Legal UncertaintyAn ongoing qui tam suit creates multi-quarter legal and reputational risk. Even without DOJ intervention, prolonged litigation can raise legal costs, distract management, and potentially affect reimbursement practices or require settlements that materially impact long‑term cash flow.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $95.11 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $9.72B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 17 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.50 (111.22% Upside)
$97.50 (111.22% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.83%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Stock 12 Month Forecast
Average Price Target
$97.50
▲(111.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.88% Insiders
15.08% Mutual Funds
0.10% Other Institutional Investors
52.01% Public Companies and Individual Investors